Newsroom
Sorted by: Latest
-
TravelX Achieves High-Growth 2025, Driving Airline Adoption of AI-Powered Post-Booking Revenue Technology
MIAMI--(BUSINESS WIRE)--TravelX, a pioneer in airline inventory and post-booking revenue management technology, provided a recap of its robust business activity throughout 2025, detailing operational achievements, product enhancements, and strategic partnerships that reshaped the company’s leading position in the market. Key Highlights: Signed new partnerships with AirAsia, Spirit Airlines, Scoot, GOL, and Cebu Pacific, and tapped into new markets across Asia Pacific, Latin America, and North A...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 05.02.2026 FKU IE00B8X9NZ57 209,100.00 GBP 8,787,547.86 42.026 ...
-
AM Best Upgrades Credit Ratings of First Net Insurance Company
OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has upgraded the Financial Strength Rating to A- (Excellent) from B++ (Good) and the Long-Term Issuer Credit Rating to “a-” (Excellent) from “bbb+” (Good) of First Net Insurance Company (First Net) (Guam). The outlook of these Credit Ratings (ratings) has been revised to stable from positive. The ratings reflect First Net’s balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, limited business profile...
-
Afya Limited Announces Medical Seats Increase in Afya Abaetetuba
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and provider of medical practice solutions in Brazil, today announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education (“MEC”) has authorized an increase of 63 medical seats for ITPAC – Instituto Tocantinense Presidente Antonio Carlos Porto S.A. (“Afya Abaetetuba”), located in the city of Abaetetuba, in t...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 05.02.2026 FEUD IE00BF2FL590 360,581.00 EUR 19,306,977.21 53.544 ...
-
NATIXIS UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wed...
-
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therap...
-
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the “Offering”) of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10....
-
OMG They’re Back Again: T-Mobile Teams Up with the Backstreet Boys for Big Game Commercial
BELLEVUE, Wash.--(BUSINESS WIRE)--T-Mobile (NASDAQ: TMUS) is back in the Big Game for the 13th consecutive year — this time, with the Backstreet Boys to tell America why it’s better over here. Featuring the iconic group alongside cameos from Druski, mgk and Pierson Fodé, T-Mobile's Big Game commercial explains how when it comes to wireless, people don’t want it any way, they want it that way — with America’s Best Network, the best value and industry-leading benefits, all with T-Mobile. Filmed i...